La Jolla Pharmaceutical Company Profile last edited on: 7/2/2013
a biopharmaceutical company, engages in the discovery and development of orally-active small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders Year Founded
1989Last Involved Year
2009Key People / Management
George F Tidmarsh -- President
Location Information
4365 Executive Drive Suite 1070
San Diego, CA 92122-1249
San Diego, CA 92122-1249
| 858-207-4264 |
| www.ljpc.com |
Public Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The company?s products include GCS-100, a Phase-1/2 clinical trial drug used for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome. In addition, the company is developing LJPC-101, a subcutaneous formulation of GCS-100; LJPC-201, an oral galectin-3 inhibitor; and LJPC-301, a monoclonal antibody designed to neutralize galectin-3. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
Extent of SBIR involvement
Synopsis: Techseeker Business Condition
Headquartered
USAEmployment
4Revenue
N/APublic/Private
Publicly TradedStock Info
OTC : LJPCReceived SBIR $$
NoTechseeker firm in the news
There are no news available.
